Breast Cancer Update Podcast Episodes Online

Loading podcasts

Fetching podcast shows and categories...

Loading page

Opening Radio and Podcast...

Ready2SERAustralia · College Radio, World Music

Live--:--

Breast Cancer Update Podcast Episodes Online | Radio and Podcast

Episodes

50 of 98 episodes

Oral SERDs for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Dr Aditya Bardia from the University of California Los Angeles and Dr Erica Mayer from Dana-Farber Cancer Institute in Boston, Massachusetts...

57:18Apr 30, 2026

HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Optimizing Biomarker Assessment and Related Treatment Decision-Making

Dr Seth Wander from Massachusetts General Hospital in Boston discusses the role of biomarker assessment in the management of HR-positive met...

01:00:13Apr 16, 2026

ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy

Dr Virginia F Borges from the University of Colorado Anschutz Medical Campus in Aurora and Dr Ian E Krop from Yale Cancer Center in New Have...

57:59Apr 14, 2026

Desmoid Tumors — Microlearning Activity 2 with Dr Ravin Ratan

Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches...

28:14Apr 7, 2026

Diabetology in Breast Cancer — Managing Hyperglycemia in Patients with Breast Cancer Receiving Agents Targeting the PI3K/AKT/PTEN Pathway

Ms Jaime Carroll from Mayo Clinic in Rochester, Minnesota, Professor Giuseppe Curigliano from the European Institute of Oncology in Milan, I...

01:15:32Mar 30, 2026

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Lajos Pusztai: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays

Dr Lajos Pusztai from Yale Cancer Center in New Haven, Connecticut, discusses recent developments with circulating tumor DNA assays in the m...

30:21Mar 18, 2026

Desmoid Tumors — Microlearning Activity 1 with Dr Ravin Ratan

Dr Ravin Ratan from The University of Texas MD Anderson Cancer Center in Houston discusses available clinical data with treatment approaches...

16:43Mar 16, 2026

Antibody-Drug Conjugates for Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, and Dr Sara M Tolaney from Dana-Farber Cancer Institute...

58:40Mar 2, 2026

Endocrine-Based Therapy for HR-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Dr Angela DeMichele from the Abramson Cancer Center in Philadelphia, Pennsylvania, Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Cen...

02:01:07Jan 27, 2026

HER2-Positive Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Prof Giuseppe Curigliano from the University of Milan in Italy, Prof Nadia Harbeck from LMU University Hospital in Munich, Germany, Dr Ian E...

01:58:18Jan 14, 2026

Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series

Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter S...

01:30:21Jan 8, 2026

Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases

Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of...

01:00:14Dec 23, 2025

Breast Cancer — Highlights from the 2025 ESMO Annual Meeting

Prof Giuseppe Curigliano from the European Institute of Oncology in Milan, Italy, and Dr Priyanka Sharma from the University of Kansas Cance...

01:27:39Dec 8, 2025

Breast Cancer — Microlearning Activity Issue 3 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with bre...

15:27Dec 5, 2025

Breast Cancer — Microlearning Activity 2 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with bre...

16:55Dec 2, 2025

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 2

Dr Rinath M Jeselsohn and Dr Joyce O’Shaughnessy review current literature and datasets exploring the use of oral selective estrogen recepto...

58:54Nov 29, 2025

Breast Cancer — Microlearning Activity 1 with Dr Priyanka Sharma: 2025 ESMO Annual Meeting Updates

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with bre...

12:49Nov 26, 2025

HR-Positive Metastatic Breast Cancer — An Interview with Dr Erika Hamilton on the Potential Role of PROTAC Estrogen Receptor Degraders

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen recepto...

58:36Nov 20, 2025

ER-Positive Metastatic Breast Cancer — A Roundtable Discussion on the Current and Future Role of Oral SERDs

Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in D...

02:30:36Nov 14, 2025

Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landsca...

01:57:51Nov 10, 2025

ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders

Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies...

41:17Nov 5, 2025

Breast Cancer — 5-Minute Journal Club Issue 4 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed anti...

15:40Oct 27, 2025

Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates

Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates i...

56:46Oct 21, 2025

HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment

Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the cu...

43:40Oct 14, 2025

Breast Cancer — An ASCO 2025 Review

Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical finding...

01:02:01Oct 7, 2025

Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-direct...

21:51Sep 29, 2025

Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management

Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metasta...

40:53Sep 23, 2025

Metastatic Triple-Negative Breast Cancer — The Selection and Sequencing of Therapy

Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negativ...

58:41Sep 18, 2025

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-d...

54:23Sep 16, 2025

Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel...

57:47Sep 15, 2025

Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD...

58:36Sep 9, 2025

Breast Cancer — 5-Minute Journal Club Issue 2 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adver...

15:43Sep 1, 2025

Brain Metastases with HER2-Positive Breast Cancer — An Interview with Dr Sarah Sammons on Optimal Management Approaches

Dr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain met...

45:42Aug 26, 2025

Breast Cancer — 5-Minute Journal Club Issue 1 with Dr Erika Hamilton: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator pe...

20:18Aug 4, 2025

Endocrine-Resistant HR-Positive Metastatic Breast Cancer — An Interview with Dr Hope S Rugo on Optimal Management

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and invest...

27:45Jul 29, 2025

Metastatic Breast Cancer — Proceedings from a Session Held During the 2025 ASCO Annual Meeting

Dr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present da...

01:57:47Jul 4, 2025

IDH-Mutant Low-Grade Glioma — An Interview with Dr Patrick Y Wen on Current and Future Management Strategies

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gli...

54:07Jun 23, 2025

For Oncology Nurses: Hormone Receptor-Positive Breast Cancer — Proceedings from the 2025 Annual ONS Congress

Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported...

01:54:49Jun 16, 2025

Breast Cancer: Additional Perspectives — Year in Review Series on Relevant New Datasets and Advances

Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusett...

01:01:12Jun 4, 2025

5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the man...

13:48May 28, 2025

5-Minute Journal Club Issue 7 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the m...

17:35May 19, 2025

Breast Cancer — Year in Review Series on Relevant New Datasets and Advances

Dr Rebecca Dent from National Cancer Centre Singapore and Dr Nancy Lin from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss i...

59:31May 6, 2025

For Oncology Nurses: Antibody-Drug Conjugates for Breast Cancer and Lung Cancer — Proceedings from the 2025 Annual ONS Congress

Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody...

01:33:02Apr 26, 2025

Hormone Receptor-Positive Metastatic Breast Cancer — An Interview with Dr Adam M Brufsky on the Impact of Biomarkers and Existing Comorbidities on the Selection of First-Line Therapy

Dr Adam M Brufsky from the University of Pittsburgh discusses first-line treatment selection for patients with HR-positive metastatic breast...

52:52Apr 25, 2025

HER2-Positive and Triple-Negative Breast Cancer — Fourth Annual National General Medical Oncology Summit

Clinical investigators discuss available data guiding the management of HER2-positive, triple-negative and localized breast cancer. CME info...

01:39:35Apr 21, 2025

HR-Positive Breast Cancer — Fourth Annual National General Medical Oncology Summit

Clinical investigators discuss available data guiding the management of hormone receptor-positive metastatic breast cancer. CME information...

01:59:29Apr 13, 2025

Breast Cancer — An Interview with Dr Adrienne G Waks on Recent Trial Updates

Dr Adrienne G Waks from Dana-Farber Cancer Institute in Boston, Massachusetts, reviews recent trial updates and their significance for the m...

54:56Apr 8, 2025

Neurofibromatosis Type 1 Plexiform Neurofibromas — An interview with Dr Christopher L Moertel

Dr Christopher L Moertel from the University of Minnesota in Minneapolis discusses the clinical presentation of and optimal management strat...

49:28Mar 28, 2025

HR-Positive Breast Cancer — An Interview with Dr Sara A Hurvitz on the Role of Endocrine-Based Therapy

Dr Sara A Hurvitz from the Fred Hutchinson Cancer Center in Seattle, Washington, summarizes data presented at the recent 2024 San Antonio Br...

01:03:10Mar 28, 2025

5-Minute Journal Club Issue 6 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent developments with oral SERDs in the man...

16:10Mar 22, 2025